ClinicalTrials.gg
CompletedNCT00626392ASA EFFECTSUpdated Sep 2, 2009Results posted

Study to Evaluate the EFFECTS of Acetylsalicylic Acid (ASA) on Niaspan®-Induced Flushing in Subjects With Dyslipidemia

A Phase 3 interventional study of niacin extended-release (NER) and aspirin (ASA) in Dyslipidemia, sponsored by Abbott. Completed at 26 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2009-09-02.

Sponsored by Abbott · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
277
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 22 studies in Dyslipidemias by Abbott — none open to participants now, none under way, none of them phase 3. Dyslipidemias · Abbott.

Enrollment
13th of 19
277 · median 382
Started
2008
with 2 others
Phase 3
15 of 22
none open now
Registered
15th of 22
by date

Among the 22 studies in Dyslipidemias by Abbott, this one is the 13th largest by enrollment of the 19 interventional ones that give a count, is one of 3 that started in 2008, is one of 15 in phase 3, and was the 15th registered.

Dyslipidemias

1,249 studies on the registry are indexed under Dyslipidemias; 177 are open to participants now.

Browse Dyslipidemias studies →

Open to participants now

None of the 22 studies in Dyslipidemias by Abbott is open now. The open studies under Dyslipidemias, anywhere →

Who these studies take

Of the 112 Dyslipidemias studies recruiting now, 55 (49%) set no upper age limit and 36 (32%) stop at 75 or younger; 11 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 22 studies in Dyslipidemias by Abbott as a file.
02

Study summary

The primary purpose of this study was to assess the effect of aspirin (ASA) on niacin extended-release (NER)-induced flushing in subjects with dyslipidemia.

03

Conditions studied

  • Dyslipidemia

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject must be 18 years of age or older.
  • If female, subject is either not of , defined as for at least one year or surgically sterile, or is of childbearing potential and must agree to practice for the duration of the study.
  • Have dyslipidemia as demonstrated by laboratory results.

Exclusion criteria

Exclusion Criteria:

  • Have glycosylated () >/= 9.0%.
  • Have nephrotic syndrome, dysproteinemias, or severe renal failure ( [GFR] \< 30 mL/minute, as calculated from ).
  • Have had unstable angina or an acute myocardial infarction (MI) within three months of the Screening Visit.
  • Have had severe peripheral artery disease as evidenced by intermittent claudication within three months of the Screening Visit.
  • Have had uncontrolled cardiac arrhythmias within three months of the Screening Visit.
  • Have symptomatic heart failure defined as dyspnea at rest or with exertion (mild peripheral edema is not exclusionary).
  • Have a systolic blood pressure measurement of > 180 mmHg or a diastolic blood pressure measurement of > 110 mmHg at the Screening or Baseline Visit.
  • Have active gout or uric acid >/= 11 mg/dL.
  • Have a history of hepatitis (acute or chronic), obstructive liver disease, or (ALT; serum glutamic pyruvic transaminase [SGPT]) or aspartate aminotransferase (AST; serum glutamic oxaloacetic transaminase [SGOT]) values >/= 1.3 times the (ULN) at the Screening Visit.
  • Have creatine phosphokinase (CPK) >/= 3 x ULN at the Screening Visit.
  • Have used an study drug or participated in an investigational study within 30 days of the Screening Visit.
  • Have a health condition or laboratory abnormality (inclusive of laboratory results at Screening Visit), which, in the opinion of the Investigator, may be adversely affected by the procedures or study medications in this study.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
277 participants (actual)

Study arms

  • Experimental
    NER 500; ASA run-in, ASA coadmin

    Aspirin (ASA) daily during run-in (1 week); ASA 30 min prior to niacin extended-release (\[NER\], 500 mg starting dose), daily during coadministration period (4 weeks)

    Drug: niacin extended-release (NER) · Drug: aspirin (ASA)

  • Experimental
    NER 500; ASA Pbo run-in, ASA coadmin

    Aspirin placebo (ASA Pbo) daily during run-in (1 week); ASA 30 min prior to niacin extended-release (\[NER\], 500 mg starting dose), daily during coadministration period (4 weeks)

    Drug: niacin extended-release (NER) · Drug: aspirin (ASA) · Drug: aspirin placebo (ASA Pbo)

  • Experimental
    NER 500; ASA Pbo run-in, ASA Pbo coadmin

    Aspirin placebo (ASA Pbo) daily during run-in (1 week); ASA Pbo 30 min prior to niacin extended-release (\[NER\], 500 mg starting dose), daily during coadministration period (4 weeks)

    Drug: niacin extended-release (NER) · Drug: aspirin placebo (ASA Pbo)

  • Experimental
    NER 1000; ASA run-in, ASA coadmin

    Aspirin (ASA) daily during run-in (1 week); ASA 30 min prior to niacin extended-release (\[NER\], 1000 mg starting dose), daily during coadministration period (4 weeks)

    Drug: niacin extended-release (NER) · Drug: aspirin (ASA)

  • Experimental
    NER 1000; ASA Pbo run-in, ASA coadmin

    Aspirin placebo (ASA Pbo) daily during run-in (1 week); ASA 30 min prior to niacin extended-release (\[NER\], 1000 mg starting dose), daily during coadministration period (4 weeks)

    Drug: niacin extended-release (NER) · Drug: aspirin (ASA) · Drug: aspirin placebo (ASA Pbo)

  • Experimental
    NER 1000; ASA Pbo run-in, ASA Pbo coadmin

    Aspirin placebo (ASA Pbo) daily during run-in (1 week); ASA Pbo 30 min prior to niacin extended-release (\[NER\], 1000 mg starting dose), daily during coadministration period (4 weeks)

    Drug: niacin extended-release (NER) · Drug: aspirin placebo (ASA Pbo)

Interventions

  • Tablets administered once daily; titrated to 2000 mg maximum dose during coadministration period

    Also known as: Niaspan

  • 325 mg tablets administered once daily

    Also known as: acetylsalicylic acid

  • Drugaspirin placebo (ASA Pbo)

    Tablets administered once daily

    Also known as: placebo

06

What researchers measure

Primary outcomes

  1. Maximum Severity of Flushing Events During Week 1 of Niacin Extended-release (NER) Treatment

    The maximum severity of flushing events subjects experienced during Week 1 of NER treatment was categorized as none, mild, moderate, severe, or very severe using the Flushing Assessment Tool via an e-diary. Flushing was assessed daily and the percentage of subjects with maximum flushing severity in each category was calculated.

    Time frame: From Baseline to end of Week 1

Secondary outcomes

  1. Maximum Severity of Flushing Events Overall During 4 Weeks of Niacin Extended-release (NER) Treatment

    The maximum severity of flushing events subjects experienced during 4 weeks of NER treatment was categorized as none, mild, moderate, severe, or very severe using the Flushing Assessment Tool via an e-diary. Flushing was assessed daily and the percentage of subjects with maximum flushing severity in each category was calculated.

    Time frame: 4 weeks

  2. Mean of Maximum Severity of Flushing Events Overall During 4 Weeks of Niacin Extended-release (NER) Treatment

    Subjects assessed the severity of flushing events on a 10-point numeric rating scale of 1-3 (mild), 4-6 (moderate), 7-9 (severe), and 10 (very severe) using the Flushing Assessment Tool via an e-diary. For subjects who did not experience flushing, a score of 0 was assigned. Flushing was assessed daily.

    Time frame: 4 weeks

  3. Mean Number of Moderate or Greater Flushing Events Per Subject Per Week Overall During 4 Weeks of Niacin Extended-release (NER) Treatment

    Flushing was assessed daily using the Flushing Assessment Tool via an e-diary and the mean number of flushing events per subject per week considered moderate or greater in severity was calculated. Flushing events were rated by the subject using a categorical scale of mild, moderate, severe, or very severe.

    Time frame: 4 weeks

07

Results

Posted Aug 25, 2009

Participant flow

Participants were enrolled at 47 study sites in the United States between February and April, 2008.

Run-in Period
Participant flow — Run-in Period
MilestoneNER 500; ASA run-in, ASA CoadminNER 500; ASA Pbo run-in, ASA CoadminNER 500; ASA Pbo run-in, ASA Pbo CoadminNER 1000; ASA run-in; ASA CoadminNER 1000; ASA Pbo run-in, ASA CoadminNER 1000; ASA Pbo run-in, ASA Pbo Coadmin
Started454444444545
Completed444341434144
Not completed113141
Withdrew: Adverse event001010
Withdrew: Withdrawal by subject011131
Withdrew: Noncompliance101000
Coadministration Period
Participant flow — Coadministration Period
MilestoneNER 500; ASA run-in, ASA CoadminNER 500; ASA Pbo run-in, ASA CoadminNER 500; ASA Pbo run-in, ASA Pbo CoadminNER 1000; ASA run-in; ASA CoadminNER 1000; ASA Pbo run-in, ASA CoadminNER 1000; ASA Pbo run-in, ASA Pbo Coadmin
Started444341434144
Completed403831363638
Not completed4510756
Withdrew: Adverse event317434
Withdrew: Withdrawal by subject110101
Withdrew: Protocol violation010110
Withdrew: Other023111

Outcome measures

PrimaryMaximum Severity of Flushing Events During Week 1 of Niacin Extended-release (NER) Treatment

The maximum severity of flushing events subjects experienced during Week 1 of NER treatment was categorized as none, mild, moderate, severe, or very severe using the Flushing Assessment Tool via an e-diary. Flushing was assessed daily and the percentage of subjects with maximum flushing severity in each category was calculated.

Time frame:
From Baseline to end of Week 1
Reported as:
Number · Percentage of Subjects
Maximum Severity of Flushing Events During Week 1 of Niacin Extended-release (NER) Treatment
Percentage of SubjectsAny Acetylsalicylic AcidNo Acetylsalicylic Acid
None5748
Mild2824
None/mild8571
Moderate1117
Severe48
Very severe14
Statistical analysis
  • Any Acetylsalicylic Acid vs No Acetylsalicylic Acid · Cochran-Mantel-Haenszel · p = 0.010 (No adjustments were made for multiple comparisons. P-values \<= 0.05 were reported as statistically significant.)
SecondaryMaximum Severity of Flushing Events Overall During 4 Weeks of Niacin Extended-release (NER) Treatment

The maximum severity of flushing events subjects experienced during 4 weeks of NER treatment was categorized as none, mild, moderate, severe, or very severe using the Flushing Assessment Tool via an e-diary. Flushing was assessed daily and the percentage of subjects with maximum flushing severity in each category was calculated.

Time frame:
4 weeks
Reported as:
Number · Percentage of Subjects
Maximum Severity of Flushing Events Overall During 4 Weeks of Niacin Extended-release (NER) Treatment
Percentage of SubjectsAny Acetylsalicylic AcidNo Acetylsalicylic Acid
None3015
Mild2814
None/Mild5830
Moderate2835
Severe1123
Very severe413
SecondaryMean of Maximum Severity of Flushing Events Overall During 4 Weeks of Niacin Extended-release (NER) Treatment

Subjects assessed the severity of flushing events on a 10-point numeric rating scale of 1-3 (mild), 4-6 (moderate), 7-9 (severe), and 10 (very severe) using the Flushing Assessment Tool via an e-diary. For subjects who did not experience flushing, a score of 0 was assigned. Flushing was assessed daily.

Time frame:
4 weeks
Reported as:
Mean · Scores on a Scale
Mean of Maximum Severity of Flushing Events Overall During 4 Weeks of Niacin Extended-release (NER) Treatment
Scores on a ScaleAny Acetylsalicylic AcidNo Acetylsalicylic Acid
Mean of Maximum Severity of Flushing Events Overall During 4 Weeks of Niacin Extended-release (NER) Treatment3.1 ± 2.865.1 ± 3.16
SecondaryMean Number of Moderate or Greater Flushing Events Per Subject Per Week Overall During 4 Weeks of Niacin Extended-release (NER) Treatment

Flushing was assessed daily using the Flushing Assessment Tool via an e-diary and the mean number of flushing events per subject per week considered moderate or greater in severity was calculated. Flushing events were rated by the subject using a categorical scale of mild, moderate, severe, or very severe.

Time frame:
4 weeks
Reported as:
Mean · Number of Events per Subject per Week
Mean Number of Moderate or Greater Flushing Events Per Subject Per Week Overall During 4 Weeks of Niacin Extended-release (NER) Treatment
Number of Events per Subject per WeekAny Acetylsalicylic AcidNo Acetylsalicylic Acid
Mean Number of Moderate or Greater Flushing Events Per Subject Per Week Overall During 4 Weeks of Niacin Extended-release (NER) Treatment0.3 ± 0.640.8 ± 1.10

Adverse events

Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Any Acetylsalicylic Acid———
No Acetylsalicylic Acid———
Most frequent serious events
Most frequent serious events
EventAny Acetylsalicylic AcidNo Acetylsalicylic Acid
Esophageal ulcerGastrointestinal disorders0/1711/85
DyspneaRespiratory, thoracic and mediastinal disorders1/1710/85
Most frequent other events
Most frequent other events
EventAny Acetylsalicylic AcidNo Acetylsalicylic Acid
FlushingVascular disorders117/17171/85
ArthralgiaMusculoskeletal and connective tissue disorders1/1713/85
Non-cardiac chest painGeneral disorders1/1712/85
Blood creatine phosphokinase increasedInvestigations0/1712/85
Blood uric acid increasedInvestigations0/1712/85
Pain in extremityMusculoskeletal and connective tissue disorders0/1712/85
RashSkin and subcutaneous tissue disorders3/1712/85
NauseaGastrointestinal disorders4/1711/85

Baseline characteristics

Age Continuous
Age Continuous(Years)NER 500; ASA run-in, ASA CoadminNER 500; ASA Pbo run-in, ASA CoadminNER 500; ASA Pbo run-in, ASA Pbo CoadminNER 1000; ASA run-in, ASA CoadminNER 1000; ASA Pbo run-in, ASA CoadminNER 1000; ASA Pbo run-in, ASA Pbo CoadminTotal
Mean55.5 ± 10.6249.0 ± 10.4851.5 ± 12.5853.7 ± 12.454.8 ± 11.0852.3 ± 12.4552.8 ± 11.73
Sex: Female, Male
Sex: Female, Male(Participants)NER 500; ASA run-in, ASA CoadminNER 500; ASA Pbo run-in, ASA CoadminNER 500; ASA Pbo run-in, ASA Pbo CoadminNER 1000; ASA run-in, ASA CoadminNER 1000; ASA Pbo run-in, ASA CoadminNER 1000; ASA Pbo run-in, ASA Pbo CoadminTotal
Female212321152123124.0
Male232020282021132.0
Region of Enrollment
Region of Enrollment(participants)NER 500; ASA run-in, ASA CoadminNER 500; ASA Pbo run-in, ASA CoadminNER 500; ASA Pbo run-in, ASA Pbo CoadminNER 1000; ASA run-in, ASA CoadminNER 1000; ASA Pbo run-in, ASA CoadminNER 1000; ASA Pbo run-in, ASA Pbo CoadminTotal
United States444341434144256.0
08

Study locations

26 sites
  • Huntsville, Alabama 35801, United States
  • Scottsdale, Arizona 85251, United States
  • Tucson, Arizona 85710, United States
  • Tucson, Arizona 85712, United States
  • Anaheim, California 92801, United States
  • Los Angeles, California 90057, United States
  • Newport Beach, California 92660, United States
  • Stockton, California 95204, United States
  • Vista, California 90057, United States
  • Westlake Village, California 91361, United States
  • Coral Gables, Florida 33134, United States
  • Jacksonville, Florida 32259, United States
  • Miami, Florida 33186, United States
  • Pembroke Pines, Florida 33027, United States
  • West Palm Beach, Florida 33407, United States
  • N. Dartmouth, Massachusetts 02747, United States
  • Rochester, New York 14609, United States
  • Charlotte, North Carolina 28262, United States
  • Winston-Salem, North Carolina 27103, United States
  • Penndel, Pennsylvania 19047, United States
  • Johnston, Rhode Island 02919, United States
  • Mt. Pleasant, South Carolina 29464, United States
  • Simpsonville, South Carolina 29681, United States
  • Colleyville, Texas 76034, United States
  • Houston, Texas 77074, United States
  • San Antonio, Texas 78229, United States
09

References and documents

Publications

  • Thakkar RB, Kashyap ML, Lewin AJ, Krause SL, Jiang P, Padley RJ. Acetylsalicylic acid reduces niacin extended-release-induced flushing in patients with dyslipidemia. Am J Cardiovasc Drugs. 2009;9(2):69-79. doi: 10.1007/BF03256578. PubMed 19331435 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2008, a primary completion of Apr 2008 and a completion of Apr 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2009, 1 year 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 21, 2008
First posted
Feb 29, 2008
Start
Feb 2008
Primary completionActual
Apr 2008
CompletionActual
Apr 2008
Results first posted
Aug 25, 2009
Last update
Sep 2, 2009
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 2, 2009, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00626392
Lead sponsor
Abbott
First posted
Feb 29, 2008
Start date
Feb 2008
Primary completion
Apr 2008
Completion
Apr 2008
Results posted
Aug 25, 2009
Last update
Sep 2, 2009

Study contacts

Roopal Thakkar, MD
study director · Abbott

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2009. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Aspirin

Start the discussion